Key Clinical Summary: Managing ARIA in Anti-Amyloid Therapy for Alzheimer’s Disease

Introduction

This education provides an overview of the practical management of amyloid-related imaging abnormalities (ARIA) in patients receiving anti-amyloid monoclonal antibody therapy for early symptomatic Alzheimer's disease. As the first class of disease-modifying treatments shown to delay disease progression, anti-amyloid therapies represent a significant clinical advancement. However, their use requires highly coordinated care pathways. Successful ARIA management hinges on system-wide synchronization—from pre-treatment counseling and standardized imaging to multidisciplinary team (MDT) coordination and emergency response protocols.

Pre-Treatment Counseling and Shared Decision-Making

Proactive and transparent shared decision-making is essential before initiating therapy to prepare patients and care partners for the practical realities of ARIA.

● Plain Language Explanations: Clinicians must clearly define ARIA-E (localized brain swelling) and ARIA-H (microhemorrhages or superficial siderosis). Patients should understand that approximately 75% of ARIA cases are asymptomatic and detected only via routine MRI monitoring. Symptomatic ARIA cases are most often of mild or moderate severity.

● Genetic Risk Stratification: Discussions must incorporate the patient’s ApoE4 carrier status, as heterozygotes and homozygotes face an elevated risk of developing ARIA.

● Setting Expectations: Establish clear expectations regarding the strict MRI surveillance schedule, clinical monitoring for symptoms, and the possibility of treatment pauses.

● Empowering Patients: Patients must be given written educational materials, a designated clinical contact, and a patient alert card detailing their therapy.

Standardized Imaging and Monitoring

Consistent and accurate imaging protocols are critical to eliminating diagnostic ambiguity and guiding appropriate treatment modifications.

● Sequence Consistency: The clinical center and imaging center must agree on standardized MRI sequences. Susceptibility-weighted imaging (SWI) is more sensitive than gradient-recalled echo (GRE) and will detect a higher baseline number of microhemorrhages. Clinicians must account for this heightened sensitivity rather than becoming overly concerned.

● Avoiding Technical Drift: Switching between MRI machines or imaging sequences during the monitoring period is highly problematic and should be avoided to ensure accurate comparative reads.

● Standardized Reporting: Radiology reports must move beyond simply noting the presence of ARIA. They must detail the exact location, size, quantity of microhemorrhages, and specific changes compared to the baseline MRI. ARIA-E is even more important.

ARIA Management and Care Pathways

Clinical management of ARIA requires a well-defined protocol to protect patients from unsafe continuations while preventing unnecessary delays in care.

● Continuation vs. Pause: If ARIA is mild (radiographic only and clinically silent), treatment can generally continue. If ARIA is radiographically moderate to severe, or accompanied by clinical symptoms, therapy should be paused, closely monitored, and reassessed for safe re-initiation once resolved.

● Avoiding the "Curse of Repetitive Meetings": While complex cases benefit from MDT discussion, care must not drift. Programs need clear timelines, named clinical leads, and established criteria for pausing, restarting, or permanently discontinuing therapy.

● System-Wide Communication: Treatment status changes must be rapidly communicated across the entire care network, including the infusion center, primary care physician, and the patient/care partner.

Emergency Protocols and Stroke Mimics

Acute neurological presentations in patients on anti-amyloid therapy require highly specialized emergency management to prevent catastrophic outcomes.

● Clinical Presentation: ARIA-E and large macrohemorrhages can present with symptoms that closely mimic a transient ischemic attack (TIA) or ischemic stroke, including sudden confusion, expressive dysphasia, focal weakness, gait instability, visual changes, and seizures.

● The Danger of Thrombolysis: Misdiagnosing ARIA as an ischemic stroke and administering thrombolytics (tPA) can lead to massive hemorrhagic stroke, irreversible neurological damage, or death.

● Diagnostic Imaging in the ED: Standard stroke protocols typically utilize CT head scans, which do not reliably capture ARIA-E or microhemorrhages. Patients on anti-amyloid therapies presenting with acute neurological symptoms must undergo MRI evaluation that includes the right sequences.

● System Safeguards: Local emergency departments must be educated about these therapies. Mandatory safeguards include highly visible flags in the electronic medical record (EMR), patient alert cards, and rapid escalation pathways connecting the ED directly to the managing memory clinic or responsible clinician.

Conclusion

Anti-amyloid therapies offer meaningful clinical benefits, and ARIA is a highly manageable risk when the healthcare system is properly prepared. Clinical success requires proactive patient counseling, rigorous adherence to standardized imaging protocols, decisive MDT management, and ironclad emergency safeguards to prevent misdiagnosis in acute settings.